HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A2831 Anti-CD59 Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD.
A2837 Anti-CD83 Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD.
A2838 Anti-CD9 Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD.
A2839 Anti-CDH1 / E-cadherin / CD324 Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD.
E4218 L-Cysteine (hydrochloride hydrate) L-Cysteine hydrochloride hydrate is an essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione, and taurine. L-Cysteine hydrochloride hydrate suppresses ghrelin and reduces appetite in rodents and humans.
A2844 Anti-Clathrin Heavy Chain / CHC Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD.
E4470 Potassium Chloride Potassium chloride is an inorganic salt commonly used in fertilizer industry. It is also extensively used as a potassium supplement.
A2596 Tilvestamab (Anti-AXL / UFO) Tilvestamab (Anti-AXL / UFO) is a humanized antibody targeting AXL.Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. MW :146.16 KD.
A2601 Amivantamab (Anti-HGFR / c-Met) Amivantamab (Anti-HGFR / c-Met) is a human bispecific antibody targeting EGFR-MET.It has immune anticancer activity in non-small cell lung cancer (NSCLC). MW :146.1 KD.
A2857 Anti-Sphingosine-1-phosphate Anti-Sphingosine-1-phosphate is a human IgG1 monoclonal anti-Sphingosine-1-phosphate antibody that targets lysosphingolipids, thereby lowering the concentration of S1P in the extracellular fluid. MW: 145.74 KD.
A2615 Anti-PMEL Anti-PMEL is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. MW :145.38 KD.
A2873 Anti-ICAM3 / CD50 Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.
A2874 Anti-MUC17 Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD.
A2627 Anti-Complement C5aR1 (G2_anti-C5aR) Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD.
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.
D4060 Mirvetuximab-MMAE Mirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD.
A2639 Anti-CEACAM6 / CD66c (NEO-201) Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD.
D4061 Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an ADC targeting GPC3 (glypican-3). It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and can be used in the research of hepatocellular carcinoma (HCC). MW :145.58 KD.
A2640 Anti-CHI3L1 Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD.
D4062 Anti-KAAG1 (ADCT-901-MMAE) Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD.